Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)

Note that you will be prompted to log in or register an account

Accession Number
HLB00620808a

Study Type
Clinical Trial

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period
November 1995 - June 2005

NHLBI Division
DCVS

Dataset(s) Last Updated
January 3, 2018

Clinical Trial URLs
https://clinicaltrials.gov/ct2/show/NCT00000558

Primary Publication URLs
https://www.ncbi.nlm.nih.gov/pubmed/15531767

Consent

Commercial Use Data Restrictions No

Data Restrictions Based On Area Of Research No

Commercial Use Specimen Restrictions No

Non-Genetic Use Specimen Restrictions Based On Area Of Use Yes

Genetic Use Of Specimens Allowed? Yes

Genetic Use Area Of Research Restrictions Yes

Specific Consent Restrictions
Consent restricts use of biospecimens to research related to predictors of coronary heart disease progression.

Objectives

To conduct a trial to test the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy.

Background

Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure.

Subjects

The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).

Conclusions

In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization. (NEJM 2004;351:2058-2068)

Additional Details

Study Population

Subjects:

Placebo: 4,132

Active Drug, Trandolapril: 4,158

Age:

	Placebo		Active drug, trandolapril		All
	N	%	N	%	N	%
46-50	91	2.20	94	2.26	185	2.23
51-55	610	14.76	629	15.13	1239	14.95
56-60	781	18.90	733	17.63	1514	18.26
61-65	817	19.77	803	19.31	1620	19.54
66-70	795	19.24	868	20.88	1663	20.06
71-75	621	15.03	620	14.91	1241	14.97
76-80	349	8.45	332	7.98	681	8.21
>=81	68	1.65	79	1.90	147	1.77

Sex:

	Placebo		Active drug, trandolapril		All
	N	%	N	%	N	%
Female	704	17.04	790	19.00	1494	18.02
Male	3428	82.96	3368	81.00	6796	81.98

Available Biospecimens

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

Visits (Vials):

03/04/2019

	Serum	Plasma	Urine	Total
Baseline	7,354	21,255	6,712	35,321
Follow-up Visit 1	55	79	35	169
Follow-up Visit 2	1,244	1,561	724	3,529
Follow-up Visit 3	701	889	388	1,978
Follow-up Visit 4	1,823	2,312	1,002	5,137
Follow-up Visit 5	1,017	1,276	545	2,838
Follow-up Visit 6	2,820	3,517	1,546	7,883
Follow-up Visit 7	1,274	1,644	675	3,593
Follow-up Visit 8	2,220	2,783	1,232	6,235
Follow-up Visit 9	427	561	230	1,218
Follow-up Visit 10	423	585	238	1,246
Follow-up Visit 11	110	154	57	321
Follow-up Visit 12	29	38	18	85
Unknown	1,511	2,097	736	4,344

Visits (Subjects):

03/04/2019

	Serum
	Total number of subjects	Average volume (ml) per subject
Baseline	3,701	0.99
Follow-up Visit 1	13	2.12
Follow-up Visit 2	251	2.48
Follow-up Visit 3	141	2.49
Follow-up Visit 4	369	2.49
Follow-up Visit 5	207	2.49
Follow-up Visit 6	571	2.47
Follow-up Visit 7	258	2.49
Follow-up Visit 8	450	2.48
Follow-up Visit 9	86	2.67
Follow-up Visit 10	86	2.63
Follow-up Visit 11	22	2.50
Follow-up Visit 12	6	2.42
Unknown	306	2.48

	Plasma
	Total number of subjects	Average volume (ml) per subject
Baseline	3,770	1.94
Follow-up Visit 1	13	2.98
Follow-up Visit 2	251	3.17
Follow-up Visit 3	140	3.25
Follow-up Visit 4	368	3.13
Follow-up Visit 5	208	3.03
Follow-up Visit 6	573	3.12
Follow-up Visit 7	260	3.24
Follow-up Visit 8	450	3.23
Follow-up Visit 9	87	3.58
Follow-up Visit 10	86	3.50
Follow-up Visit 11	22	3.76
Follow-up Visit 12	6	2.83
Unknown	306	3.48

	Urine
	Total number of subjects	Average volume (ml) per subject
Baseline	3,367	11.32
Follow-up Visit 1	12	14.58
Follow-up Visit 2	242	14.96
Follow-up Visit 3	130	14.92
Follow-up Visit 4	335	14.96
Follow-up Visit 5	184	14.81
Follow-up Visit 6	516	14.98
Follow-up Visit 7	225	15.00
Follow-up Visit 8	413	14.92
Follow-up Visit 9	77	14.94
Follow-up Visit 10	80	14.88
Follow-up Visit 11	19	15.00
Follow-up Visit 12	6	15.00
Unknown	244	15.30

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.

Resources Available

Specimens and Study Datasets

Study Catalog

Study Publications (35)

Materials Available

Plasma
Serum
Urine
More Details

Study Documents

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.